Published in:
Open Access
06-04-2022 | Human Papillomavirus | Original Article – Cancer Research
Blimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2
Authors:
Mayumi Saito, Aarthi Rajesh, Carrie Innes, Rachael van der Griend, Peter Fitzgerald, Bryony Simcock, Peter Sykes, Merilyn Hibma
Published in:
Journal of Cancer Research and Clinical Oncology
|
Issue 8/2022
Login to get access
Abstract
Background
Progression of cervical intraepithelial neoplasia (CIN) to higher grade disease is associated with persistent human papillomavirus (HPV) infection and an absence of immune-mediated regression. However, the immune microenvironment that distinguishes progression from persistent or regressing lesions has not been well defined.
Methods
A total of 69 patients under the age of 25 with high-risk HPV-positive cytology and biopsy-confirmed p16-positive CIN2 were included in the study. Biopsies were stained using 20 antibodies to a range of immune markers. Based on a 2-year follow-up, samples were analysed in “progressor” (CIN3 +) or “persister/regressor” (CIN1, 2 or normal) groups.
Results
Progression was most strongly associated with Blimp-1 positive cell staining in the lesion (P = 0.0019) and with low numbers of infiltrating CD4 cells in the dermal region beneath the lesion (P = 0.0022). The presence of CD4, CD8 and T bet-positive cells in the dermal region most strongly correlated with CD11c cells in the persister/regressor but not the progressor group.
Conclusion
High numbers of Blimp-1 + cells in CIN2 lesions may predict progression to more severe disease. Measurement of Blimp-1 may have diagnostic utility for the determination of the need to treat women with cervical pre-cancer.
Highlights
CIN2 progression is associated with high numbers of Blimp-1 positive cells in the lesion. Detection of Blimp-1 in the lesion may have utility as a prognostic test to inform the need to treat CIN2.